Elekta October 2022
This year Elekta celebrates 50 years of innovation as a company and marks this anniversary by continuing to innovate. In May this year, they introduced their new stereotactic radiosurgery system, Elekta Esprit*, at the European Society for Radiotherapy and Oncology (ESTRO) 2022 and presented it again at the ISRS 2022 congress in Milan in June. Based on decades of unrivalled Leksell Gamma Knife development, Elekta Esprit evolves to the next level and honours the legacy of Lars Leksell’s innovation and dedication to provide gentler brain treatment.
With over 50 years of real-world Leksell Gamma Knife evidence, Esprit is trusted to continue to lead the way in intracranial radiosurgery – transforming treatment protocols and supporting clinicians and researchers to drive the standard of care forward.
Elekta Esprit received CE mark in August making it available for European countries and other countries that recognise CE mark. In addition, the system is pending FDA 510(k) clearance.
The new stereotactic headframe Leksell Vantage is also integrated with Elekta Esprit. The open face design of Vantage allows the patient to eat, drink and read while waiting, making the patient experience as comfortable as possible. The non-metallic materials of the frame itself and associated CT and MR imaging accessories reduce image artifacts in MR and CT planning studies. This increases the ability to see more valuable brain anatomy and vasculature. In addition, with its multi-channel neuro head coil, Vantage enables faster MRI image acquisition, and the frame increases the potential to acquire high quality stereotactic images with 3T MRI scanners.
*Elekta Esprit is CE marked and pending U.S. FDA 510(k) clearance, with limited global availability.